Evidence map›Paper›PMID 31182141›Full record

ArticleBMC research notes2019

Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?

Javier Sánchez Ramírez, Mónica Bequet-Romero, Yanelys Morera Díaz, Francisco Hernández-Bernal, Marta Ayala Avila

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Javier Sánchez RamírezDepartment of Pharmaceuticals, Center for Genetic Engineering and Biotechnology, Ave 31 e/158 y 190, Playa, P.O. Box 6162, Havana, Cuba. javier.sanchez@cigb.edu.cu.ORCID http://orcid.org/0000-0003-3263-5062
Mónica Bequet-RomeroDepartment of Pharmaceuticals, Center for Genetic Engineering and Biotechnology, Ave 31 e/158 y 190, Playa, P.O. Box 6162, Havana, Cuba.
Yanelys Morera DíazDepartment of Pharmaceuticals, Center for Genetic Engineering and Biotechnology, Ave 31 e/158 y 190, Playa, P.O. Box 6162, Havana, Cuba.
Francisco Hernández-BernalDepartment of Clinical Research, Center for Genetic Engineering and Biotechnology, Ave 31 e/158 y 190, Playa, P.O. Box 6162, Havana, Cuba.
Marta Ayala AvilaDepartment of Pharmaceuticals, Center for Genetic Engineering and Biotechnology, Ave 31 e/158 y 190, Playa, P.O. Box 6162, Havana, Cuba.
Centro de Ingeniería Genética y Biotecnología · CU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesVascular endothelial growth factor (VEGF) is involved in physiological angiogenesis, but also is considered one of the key factors that promotes tumor angiogenesis. CIGB-247 is a VEGF-based vaccine that has been evaluated in phase I clinical trial patients with advanced solid tumors. This specific active immunotherapy is able to reduce platelet VEGF levels; however it is unknown whether this effect leads to a decrease in VEGF below the levels that can be observed in healthy individuals. The objective of the present study is to investigate platelet VEGF levels in cancer patients vaccinated with CIGB-247, and then compare these values with those obtained in healthy individuals. To achieve this, platelet VEGF levels of 62 cancer patients and 93 healthy individuals were compared. Cancer patients were those individuals recruited in CENTAURO and CENTAURO-2 clinical trials.

resultsBefore vaccination, platelets of cancer patients carried more VEGF than the levels seen in platelet of healthy individuals. However, after vaccination, cancer patients had platelet VEGF values within the range established by healthy individuals, indicating that the antibody response elicited by CIGB-247 is not able to induce a complete suppression of VEGF. Vaccination with CIGB-247 helps to normalize VEGF levels within platelets.

Indexed as

Adjuvants, ImmunologicAdolescentAdultAgedBlood PlateletsCancer VaccinesCase-Control StudiesFemaleGene ExpressionHumansImmunity, HumoralImmunotherapy, ActiveMaleMiddle AgedNeoplasmsNeovascularization, PathologicAdjuvants, ImmunologicCancer VaccinesVascular Endothelial Growth Factor AVEGFA protein, humanCIGB-247Phase I clinical trialPlateletsSpecific active immunotherapyVEGF vaccine

Identifiers

PMID31182141
PMCPMC6558718
OpenAlexW2949405851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.